| +0.63 / +1.68%|
Tetraphase Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company's lead product candidate, eravacycline is a fully synthetic tetracycline derivative that is developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. It has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
|Guy MacDonald||President, Chief Executive Officer & Director|
|John Craig Thompson||Chief Operating Officer|
|David Charles Lubner||Chief Financial Officer & Senior Vice President|
|Patrick Taylor Horn||Chief Medical Officer|
|Magnus Ronn||Senior VP-Chemistry, Manufacturing & Control|